Comprehensive Report on Sintilimab (TYVYT®): A PD-1 Inhibitor

Executive Summary

Sintilimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that functions as an immune checkpoint inhibitor by targeting the programmed cell death protein 1 (PD-1) receptor. Developed through a strategic collaboration between China-based Innovent Biologics and the global pharmaceutical firm Eli Lilly and Company, Sintilimab is engineered for high-affinity binding and sustained receptor occupancy. Its mechanism of action involves blocking the interaction between PD-1 on T-cells and its ligands (PD-L1 and PD-L2), thereby restoring the host's anti-tumor immune response.

Marketed in China as TYVYT®, Sintilimab has achieved significant clinical and commercial success, securing numerous approvals from the National Medical Products Administration (NMPA) for a wide range of high-incidence malignancies. These include classical Hodgkin's lymphoma, non-small cell lung cancer (both squamous and non-squamous subtypes), hepatocellular carcinoma, esophageal squamous cell carcinoma, gastric cancer, and endometrial cancer. Its inclusion in China's National Reimbursement Drug List (NRDL) for most of these indications has cemented its position as a cornerstone of immuno-oncology therapy in the country.

This success in China stands in stark contrast to its regulatory experience in the United States. In March 2022, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter for Sintilimab's application in non-small cell lung cancer. The decision was based on the agency's view that the pivotal clinical trial, conducted exclusively in China, lacked applicability to the diverse U.S. patient population and utilized a comparator arm that did not reflect the current U.S. standard of care. This outcome highlights a critical divergence in regulatory philosophies between major global markets and underscores the challenges facing pharmaceuticals developed outside of traditional Western clinical trial ecosystems. Sintilimab thus serves as a key case study in the complexities of global drug development and the imperative for multiregional, diverse clinical data to support worldwide registration.

Introduction to Sintilimab (TYVYT®): A Novel PD-1 Inhibitor

Drug Identification and Classification

Sintilimab is a high-purity, biotech-derived therapeutic agent classified as a fully human immunoglobulin G4 (IgG4​) kappa isotype monoclonal antibody.[1] It is produced using recombinant DNA technology in Chinese Hamster Ovary (CHO) cells.[2] In China, the drug is marketed under the brand name TYVYT® (sintilimab injection).[5] As an antineoplastic agent, it belongs to the therapeutic class of PD-1/PD-L1 inhibitors.[4]

Table 1: Sintilimab Drug Profile Summary

Attribute	Details	Source(s)
Name	Sintilimab	1
Brand Name (China)	TYVYT®	5
DrugBank ID	DB15765	1
Type	Biotech; Fully Human IgG4 Monoclonal Antibody	1
CAS Number	2072873-06-2	1
Synonyms/Codes	IBI 308, LY-3342901, Anti-PD-1 monoclonal antibody IBI308, Xindili Dankang	1
UNII	8FU7FQ8UPK	1
KEGG	D12119	1
Target	Programmed cell death protein 1 (PD-1/PDCD1/CD279)	3
Developers	Innovent Biologics, Eli Lilly and Company	1

Development and Corporate Partnership

The development of Sintilimab is the result of a landmark strategic collaboration between Innovent Biologics, Inc., a biopharmaceutical company headquartered in Suzhou, China, and Eli Lilly and Company, a global pharmaceutical leader.[1] The partnership, initiated in March 2015, was a groundbreaking agreement for the co-development and co-commercialization of oncology medicines, including Sintilimab, in China.[7] This collaboration made TYVYT® the only PD-1 antibody in the Chinese market to be branded by both a domestic and a global pharmaceutical company, a significant commercial distinction.[6]

Building on their success in China, the alliance was expanded in August 2020. Under the expanded agreement, Lilly obtained an exclusive license for Sintilimab in all geographies outside of China, with plans to pursue registration in the U.S. and other markets.[7] This move signaled a clear ambition to establish Sintilimab as a global therapeutic agent, leveraging Innovent's development and Lilly's global regulatory and commercialization expertise.

Mechanism of Action and Pharmacological Profile

Core Mechanism: PD-1 Checkpoint Blockade

Sintilimab's therapeutic effect is derived from its function as an immune checkpoint inhibitor. Its primary molecular target is the programmed cell death protein 1 (PD-1) receptor, which is expressed on the surface of activated T-cells.[2] In many cancers, tumor cells and other cells within the tumor microenvironment upregulate the expression of PD-1 ligands, namely PD-L1 and PD-L2.[4] The binding of these ligands to the PD-1 receptor on T-cells initiates an inhibitory signaling cascade that suppresses T-cell proliferation, cytokine production, and cytotoxic activity, effectively allowing the tumor to evade immune surveillance.[4]

Sintilimab physically binds to the PD-1 receptor, thereby acting as a competitive antagonist that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.[3] This blockade releases the "brakes" on the T-cell, restoring its endogenous anti-tumor capabilities and reactivating the immune system to recognize and eliminate cancer cells.[2]

Molecular Binding Characteristics

In a competitive immuno-oncology landscape, the molecular engineering of an antibody can provide a critical therapeutic advantage. Sintilimab was developed to be a "me-better" agent rather than a "me-too" drug, a strategy reflected in its distinct binding properties. It demonstrates a very high binding affinity for the human PD-1 receptor, with a dissociation constant (KD​) value of 74 pM.[3]

Structural analysis has revealed that Sintilimab binds to a unique conformational epitope on PD-1. This interaction is characterized by highly complementary, hydrophobic surfaces formed by the antibody's complementarity-determining regions (CDRs). The interactive surface area on Sintilimab is reportedly almost double that of the first-generation PD-1 inhibitors nivolumab and pembrolizumab.[17] This unique structural engagement is believed to confer a significantly slower off-rate from the PD-1 receptor compared to these other agents.[17] A slower off-rate could theoretically translate to a more sustained PD-1 blockade on T-cells, potentially leading to a more durable and potent anti-tumor immune response from a single dose. These molecular-level distinctions form a core part of the drug's value proposition, positioning it as a potentially superior therapeutic option.

Pharmacodynamics and In Vitro/In Vivo Activity

The favorable binding kinetics of Sintilimab translate to potent pharmacodynamic activity. In vitro, Sintilimab has been shown to induce high levels of interferon-gamma (IFN−γ) and interleukin-2 (IL−2) secretion in primary T-cell assays, indicative of robust T-cell activation.[3] In vivo studies using humanized mouse models have demonstrated that Sintilimab achieves high and sustained PD-1 receptor occupancy, exceeding 90% in both peripheral T-cells and critical tumor-infiltrating T-cells (TILs).[3] This high level of target engagement resulted in more effective tumor growth inhibition in preclinical models compared to comparator agents.[3]

Pharmacokinetics (PK)

While comprehensive human pharmacokinetic data is not fully detailed in the available materials, some key aspects can be summarized. The recommended dosage for its initial approval in China was 200 mg administered as an intravenous infusion every 3 weeks, a regimen that has been maintained in many subsequent combination therapy trials.[18] A Phase I clinical trial (NCT04177290) was conducted to confirm the PK similarity between Sintilimab produced via two different manufacturing processes, though specific results like half-life in humans were not reported.[21]

Preclinical data in PD-1 knockout mice indicated a serum half-life of 35.6 hours.[22] In cynomolgus monkeys, Sintilimab exhibited PK characteristics typical of an IgG antibody.[23] Importantly, the potential for immunogenicity appears low; in a study involving 381 human subjects, only 0.52% tested positive for anti-drug antibodies (ADA), suggesting that ADA-mediated clearance is unlikely to be a significant clinical issue.[22]

Clinical Development Program: Efficacy and Safety Analysis Across Indications

The clinical validation of Sintilimab is built upon a comprehensive and ambitious series of studies, primarily under the "ORIENT" program. This program has systematically evaluated Sintilimab's efficacy and safety across a broad spectrum of high-incidence cancers, both as a monotherapy and, more frequently, as a backbone for combination regimens. This strategic approach has been instrumental in securing its numerous regulatory approvals in China.

Table 2: Summary of Key Phase III Clinical Trials (ORIENT Series)

Trial ID (NCT)	Indication	Phase	Primary Endpoint	Key Result (HR or %)
ORIENT-1 (NCT03114683)	Relapsed/Refractory Classical Hodgkin's Lymphoma (r/r cHL)	II	ORR	80.4%
ORIENT-11 (NCT03607539)	1L Non-Squamous NSCLC	III	PFS	HR: 0.482
ORIENT-12 (NCT03629925)	1L Squamous NSCLC	III	PFS	HR: 0.536
ORIENT-15 (NCT03748134)	1L Esophageal Squamous Cell Carcinoma (ESCC)	III	OS	HR: 0.63
ORIENT-16 (NCT03745170)	1L Gastric/GEJ Adenocarcinoma	III	OS	HR: 0.77
ORIENT-31 (NCT03802240)	EGFR-mutated NSCLC post-TKI	III	PFS	HR: 0.464 (4-drug vs. chemo)

A. Relapsed/Refractory Classical Hodgkin's Lymphoma (r/r cHL)

The ORIENT-1 trial (NCT03114683) was the pivotal, single-arm, Phase II study that led to Sintilimab's first regulatory approval.[17] In heavily pre-treated patients who had failed at least two prior lines of systemic chemotherapy, Sintilimab monotherapy demonstrated a high degree of efficacy. The primary endpoint, Objective Response Rate (ORR) assessed by an Independent Radiological Review Committee (IRRC), was 80.4%.[17] The Disease Control Rate (DCR) was an exceptional 97.8%.[17] Long-term follow-up data at a median of 26.7 months confirmed the durability of these responses, showing a median Progression-Free Survival (PFS) of 18.6 months and a 2-year Overall Survival (OS) rate of 96.3%.[25] The treatment was well-tolerated, with Grade 3-4 Treatment-Emergent Adverse Events (TEAEs) occurring in 25% of patients.[24]

B. First-Line Non-Small Cell Lung Cancer (NSCLC)

Following its initial success, the clinical development program for Sintilimab strategically pivoted to establishing it as a first-line therapy in combination with standard chemotherapy for NSCLC, the most common cancer type. This "combination is king" approach proved highly effective, embedding Sintilimab into the standard of care by demonstrating superiority over chemotherapy alone.

• Non-Squamous NSCLC (ORIENT-11; NCT03607539): This randomized, double-blind, Phase III trial was foundational for Sintilimab's expansion. It demonstrated that adding Sintilimab to a standard pemetrexed and platinum-based chemotherapy regimen resulted in a statistically significant and clinically meaningful improvement in median PFS, the primary endpoint. The Sintilimab arm achieved a median PFS of 8.9 months compared to 5.0 months for the placebo-plus-chemotherapy arm, corresponding to a Hazard Ratio (HR) of 0.482 (p<0.00001).[26] This survival benefit was consistent across all predefined subgroups, including patients with low or negative PD-L1 expression.[28]
• Squamous NSCLC (ORIENT-12; NCT03629925): A similar Phase III trial design was used for squamous NSCLC, where Sintilimab was added to a gemcitabine and platinum-based chemotherapy backbone. This study also met its primary endpoint, showing a significant PFS improvement with a median PFS of 5.5 months in the Sintilimab arm versus 4.9 months in the placebo arm (HR 0.536, p<0.00001).[30]
• EGFR-Mutated NSCLC Post-TKI Failure (ORIENT-31; NCT03802240): This trial addressed a critical unmet need. It evaluated Sintilimab in combination with chemotherapy, with or without a bevacizumab biosimilar, in patients with EGFR-mutated NSCLC who had progressed on prior tyrosine kinase inhibitor (TKI) therapy. The results were highly positive, with the four-drug regimen (Sintilimab + bevacizumab biosimilar + chemotherapy) significantly improving median PFS to approximately 7.2 months versus 4.3 months for chemotherapy alone (HR 0.51, p<0.0001).[33] This trial effectively carved out a new market niche for Sintilimab in a hard-to-treat patient population.

C. First-Line Esophageal Squamous Cell Carcinoma (ESCC)

The ORIENT-15 trial (NCT03748134), a global, randomized, Phase III study, established Sintilimab plus chemotherapy as a new first-line standard of care for advanced or metastatic ESCC.[35] The study met its primary endpoint of OS, demonstrating that the Sintilimab-chemotherapy combination significantly prolonged median OS to 16.7 months compared to 12.5 months for chemotherapy alone (HR 0.63,

p<0.001).[14] A significant benefit in median PFS was also observed (7.2 months vs. 5.7 months; HR 0.56,

p<0.001).[14]

D. First-Line Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

The ORIENT-16 trial (NCT03745170) successfully demonstrated the benefit of adding Sintilimab to first-line chemotherapy (capecitabine and oxaliplatin) for unresectable, locally advanced, or metastatic G/GEJ adenocarcinoma.[37] The trial met its primary endpoint of OS for both the overall patient population and a prespecified subgroup with higher PD-L1 expression. In the intent-to-treat population, the median OS was 15.2 months for the Sintilimab arm versus 12.3 months for the placebo arm (HR 0.77,

p=0.009).[38] The benefit was more pronounced in patients with a PD-L1 Combined Positive Score (CPS) of 5 or greater, with a median OS of 18.4 months versus 12.9 months (HR 0.66,

p=0.002).[38]

E. Advanced Endometrial Cancer

Based on the results of the FRUSICA-1 Phase II study, Sintilimab in combination with the TKI fruquintinib received conditional NMPA approval for patients with advanced endometrial cancer who have failed prior systemic therapy.[41] The combination regimen demonstrated an ORR of 35.6%, a median PFS of 9.5 months, and a median OS of 21.3 months in this difficult-to-treat population.[41]

F. Overview of Other Investigational Programs

The clinical development of Sintilimab continues at a rapid pace, with a robust pipeline exploring its use in numerous other malignancies. This broad lifecycle management strategy includes ongoing trials in head and neck squamous cell carcinoma (Phase II), glioblastoma, cancer of unknown primary, nasopharyngeal carcinoma, ovarian cancer, and various solid tumors, often testing novel combination strategies with other targeted agents, immunotherapies, or locoregional treatments.[44]

Comprehensive Safety and Tolerability Profile

General Safety Overview

Across its extensive clinical development program, Sintilimab has demonstrated a safety profile that is generally manageable and consistent with the known toxicities of the PD-1 inhibitor class.[3] Several analyses and real-world studies suggest that Sintilimab may have a comparable or even more favorable safety profile when compared to other PD-1 inhibitors like nivolumab and pembrolizumab, a potential advantage that may be linked to its fully human IgG4 structure designed to minimize off-target effects.[10]

Common Adverse Events

The most frequently reported adverse events in patients receiving Sintilimab are immune-mediated and reflect the on-target mechanism of T-cell activation. Common TEAEs reported across multiple clinical trials include pyrexia (fever), thyroid dysfunction (hypothyroidism), rash, asthenia (fatigue), and elevations in liver enzymes.[1] When used in combination with chemotherapy, hematologic toxicities such as anemia, neutropenia, and thrombocytopenia are also highly prevalent.[14]

Immune-Related Adverse Events (irAEs)

As with all immune checkpoint inhibitors, the therapeutic activation of the immune system can lead to inflammatory side effects in various organ systems, known as immune-related adverse events (irAEs). While most irAEs are low-grade (Grade 1-2) and manageable, some can be severe, life-threatening, and require prompt intervention.[51]

• Incidence: The overall incidence of irAEs is higher in patients receiving Sintilimab compared to placebo, but the rate of severe (Grade ≥3) irAEs is relatively low in most studies.[14]
• Specific irAEs of Clinical Concern:
• Myocarditis: Although rare, immune-mediated myocarditis is one of the most serious complications of ICI therapy due to its high mortality rate. There have been case reports of sintilimab-induced myocarditis, presenting with symptoms like dysphagia and elevated cardiac enzymes, which necessitated permanent discontinuation of the drug and aggressive treatment with high-dose corticosteroids.[52]
• Hypophysitis: Inflammation of the pituitary gland is another rare but serious endocrine irAE. A reported case of Grade 4 hypophysitis induced by Sintilimab presented with severe fatigue, altered mental status, and symptoms of diabetes insipidus. Management required high-dose intravenous dexamethasone followed by a long-term prednisone taper.[54]
• Severe Cutaneous Adverse Reactions (SCARs): Life-threatening skin reactions such as Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS) have been reported in patients treated with Sintilimab. These events require immediate cessation of the drug and intensive care, including high-dose corticosteroids and supportive measures.[51]
• Pneumonitis: Inflammation of the lungs is a well-recognized and potentially fatal irAE of the PD-1 inhibitor class. It was reported as one of the most common serious adverse events in the ORIENT-1 trial.[24]

Management of irAEs

The management of irAEs is guided by their severity. For mild (Grade 1) events, treatment with Sintilimab may often continue with close monitoring. For moderate (Grade 2) to severe (Grade 3-4) irAEs, the standard approach involves withholding or permanently discontinuing Sintilimab and initiating systemic corticosteroids (e.g., prednisone at 1-2 mg/kg/day or equivalent). A slow taper of corticosteroids over at least 4-6 weeks is crucial to prevent recurrence. In cases that are refractory to steroids, other immunosuppressive agents or treatments such as intravenous immunoglobulin (IVIG) may be considered.[16]

Global Regulatory Landscape and Market Access

A. National Medical Products Administration (NMPA) of China

Sintilimab's journey in China has been a story of remarkable regulatory and commercial success. It received its first approval from the NMPA in December 2018 for the treatment of relapsed or refractory classical Hodgkin's lymphoma.[5] This was followed by an unprecedented series of rapid approvals for first-line indications in several of China's most prevalent cancers.

A key factor in its commercial success was its early and broad inclusion in China's National Reimbursement Drug List (NRDL). In 2019, TYVYT® became the first and only PD-1 inhibitor to be included in the NRDL, dramatically improving its accessibility and affordability.[7] As of late 2024, seven of its eight approved indications are covered by the NRDL, making it the only PD-1 inhibitor reimbursed for the first-line treatment of five major cancer types.[42]

Table 3: NMPA Approved Indications for Sintilimab (TYVYT®)

Approval Date	Indication	Line of Therapy	Treatment Regimen	NRDL Status	Supporting Trial
Dec 2018	Relapsed/refractory classic Hodgkin's lymphoma (r/r cHL)	After ≥2 lines of systemic chemotherapy	Monotherapy	Yes	ORIENT-1
Feb 2021	Non-squamous non-small cell lung cancer (NSCLC)	First-line (EGFR/ALK wild-type)	+ Pemetrexed & Platinum Chemotherapy	Yes	ORIENT-11
Jun 2021	Squamous NSCLC	First-line	+ Gemcitabine & Platinum Chemotherapy	Yes	ORIENT-12
Jun 2021	Hepatocellular Carcinoma (HCC)	First-line	+ Bevacizumab Biosimilar (BYVASDA®)	Yes	ORIENT-32
Jun 2022	Esophageal Squamous Cell Carcinoma (ESCC)	First-line	+ Cisplatin & Paclitaxel/5-FU Chemotherapy	Yes	ORIENT-15
Jun 2022	Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma	First-line	+ Fluorouracil & Platinum Chemotherapy	Yes	ORIENT-16
May 2023	EGFR-mutated Non-squamous NSCLC	Post-EGFR-TKI Progression	+ Bevacizumab Biosimilar & Chemotherapy	Yes	ORIENT-31
Dec 2024	Advanced Endometrial Cancer (pMMR)	Post-systemic therapy	+ Fruquintinib	Conditional	FRUSICA-1

B. U.S. Food and Drug Administration (FDA)

The attempt to bring Sintilimab to the U.S. market resulted in a significant regulatory setback that highlights a fundamental "globalization gap" in pharmaceutical development. In May 2021, the FDA accepted the Biologics License Application (BLA) for Sintilimab plus chemotherapy for first-line nonsquamous NSCLC, based on the positive ORIENT-11 trial.[29] However, in March 2022, the agency issued a Complete Response Letter (CRL), formally denying the application.[11]

The rejection was not based on a failure of the drug itself, but on the context and applicability of the clinical evidence provided. The FDA's Oncologic Drugs Advisory Committee (ODAC) had previously voted 14-to-1 against approval, citing several critical deficiencies in the application.[13] The core issues were:

1. Lack of Diversity and Applicability: The ORIENT-11 trial was conducted exclusively in China, with a 100% Asian patient population. The FDA and ODAC concluded that this data could not be generalized to the more diverse racial and ethnic makeup of the U.S. population.[13]
2. Outdated Standard of Care: The trial's comparator arm was chemotherapy alone. By the time of the BLA review, the established first-line standard of care in the U.S. was already a PD-1 inhibitor (pembrolizumab) combined with chemotherapy, a regimen that had demonstrated a clear overall survival benefit in the KEYNOTE-189 trial. The FDA viewed the ORIENT-11 design as not reflective of contemporary U.S. clinical practice.[28]
3. Inappropriate Primary Endpoint: The trial used Progression-Free Survival (PFS) as its primary endpoint. The FDA stated that for this indication, where an OS benefit had already been established by an approved therapy, OS was the only acceptable primary endpoint to demonstrate clinical benefit.[28]

This divergence illustrates two different regulatory philosophies. The NMPA's approval of the ORIENT-11 data reflects a focus on addressing national health needs with robust, locally generated data. The FDA's rejection reflects a globalist and comparative framework, requiring new drugs to demonstrate their value against the current, best-available therapy in a patient population representative of the U.S. The FDA ultimately recommended that the sponsors conduct a new, multiregional clinical trial directly comparing Sintilimab to the U.S. standard of care.[13]

Table 4: Comparative Analysis of FDA BLA Submission (ORIENT-11) vs. U.S. Standard of Care (KEYNOTE-189)

Attribute	ORIENT-11 (Sintilimab)	KEYNOTE-189 (Pembrolizumab)
Patient Population	100% Asian (China only)	Multiregional, diverse ethnicity
Comparator Arm	Placebo + Chemotherapy	Placebo + Chemotherapy
Primary Endpoint	Progression-Free Survival (PFS)	Overall Survival (OS) & PFS
Median OS Result	Not Reached vs. 16.8 mo (Updated)	22.0 mo vs. 10.7 mo
Median PFS Result	8.9 mo vs. 5.0 mo (HR 0.482)	9.0 mo vs. 4.9 mo (HR 0.48)

C. European Medicines Agency (EMA)

Sintilimab's regulatory engagement in Europe is in its early stages and it does not currently have marketing authorization. On February 28, 2020, the EMA granted Sintilimab an orphan drug designation for the treatment of Adult T-cell leukemia/lymphoma, a rare malignancy.[59] This designation provides incentives and regulatory support for the development of drugs for rare diseases but is not an approval for marketing.[60] Additionally, in April 2021, the EMA granted a waiver for a Paediatric Investigation Plan (PIP) for Sintilimab in lung cancer, indicating some level of regulatory interaction for this indication.[62]

Competitive Landscape and Comparative Analysis

Sintilimab operates in a highly competitive global market for PD-1/PD-L1 inhibitors, which includes well-entrenched blockbuster drugs such as pembrolizumab (Keytruda) and nivolumab (Opdivo). In China, it also competes with other domestically developed PD-1 inhibitors like camrelizumab and tislelizumab.

Direct Head-to-Head Data

Direct comparative data is crucial for assessing a drug's relative performance. The CTONG1901 trial (NCT04252365) was a randomized Phase II study that provided the first head-to-head comparison of Sintilimab versus pembrolizumab as a first-line treatment for advanced NSCLC.[63] The results demonstrated comparable efficacy and safety between the two agents. The ORR for patients receiving any Sintilimab-based regimen was 52.9%, compared to 32.4% for pembrolizumab-based regimens, a difference that was not statistically significant (

p=0.14). Key secondary endpoints, including DCR, PFS, and OS, were also found to be comparable between the two drugs.[64] This trial provides important evidence suggesting that Sintilimab is a non-inferior alternative to a global standard of care.

Indirect Comparisons and Meta-Analyses

In the absence of multiple large head-to-head trials, indirect comparisons and meta-analyses provide valuable context. A meta-analysis that evaluated six different PD-1/PD-L1 inhibitors for first-line non-squamous NSCLC concluded that Sintilimab, when combined with chemotherapy, showed a comparable efficacy and safety profile to combinations involving pembrolizumab, atezolizumab, and tislelizumab.[66] Similarly, a real-world study conducted in China found no significant differences in ORR or median PFS among first-line NSCLC patients treated with camrelizumab, pembrolizumab, tislelizumab, or sintilimab.[63] Multiple reviews also suggest that Sintilimab has similar anti-tumor effects to nivolumab and pembrolizumab, but with the potential for a more favorable safety profile.[10]

Strategic Analysis and Future Outlook

Conclusion

Sintilimab represents a major achievement in pharmaceutical development, showcasing the ability to create a highly effective, molecularly distinct immuno-oncology agent that can achieve market dominance within a major national healthcare system. Its success in China is a direct result of a well-executed clinical strategy that focused on generating robust data in high-incidence cancers through combination therapy trials, coupled with a strategic partnership that facilitated rapid regulatory approvals and broad reimbursement access through the NRDL.

However, the global trajectory of Sintilimab has been fundamentally altered by the FDA's 2022 Complete Response Letter. This decision has established a clear and challenging precedent, indicating that clinical data generated from a single, non-diverse population will not be sufficient for U.S. approval, especially in therapeutic areas with established standards of care. This "globalization gap" underscores the increasing complexity and cost of developing drugs for a multi-polar world with divergent regulatory expectations.

The future for Sintilimab will likely follow a dual path. In China, it is poised to continue its expansion through further label extensions and the development of novel combination therapies, solidifying its role as a standard-of-care backbone. Its global future, particularly in the U.S. and E.U., is contingent upon the willingness of its developers to invest in new, costly, and lengthy multiregional clinical trials that are designed to meet the specific evidentiary requirements of Western regulators. The journey of Sintilimab will therefore remain a critical case study for the global pharmaceutical industry, illustrating both the immense potential of emerging biopharma ecosystems and the significant hurdles that remain in translating national success into a global therapeutic reality.

Works cited

1. Sintilimab - Wikipedia, accessed July 18, 2025, https://en.wikipedia.org/wiki/Sintilimab
2. Sintilimab (anti-PD-1) - Selleck Chemicals, accessed July 18, 2025, https://www.selleckchem.com/products/sintilimab-anti-pd-1.html
3. Sintilimab (IBI308) | PD-1/PD-L1 Inhibitor | MedChemExpress, accessed July 18, 2025, https://www.medchemexpress.com/sintilimab.html
4. Tyvyt (sintilimab) dosing, indications, interactions, adverse effects ..., accessed July 18, 2025, https://reference.medscape.com/drug/tyvyt-sintilimab-4000229
5. Sintilimab: First Global Approval - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/30742278/
6. Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors - HUTCHMED, accessed July 18, 2025, https://www.hutch-med.com/innovent-and-chi-med-expand-global-collaboration-to-evaluate-the-combination-of-sintilimab-and-surufatinib-in-solid-tumors/
7. Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications, accessed July 18, 2025, https://investor.lilly.com/news-releases/news-release-details/innovent-and-lilly-announce-successful-expansion-sintilimab
8. Sintilimab - Eli Lilly and Company/Innovent Biologics - AdisInsight - Springer, accessed July 18, 2025, https://adisinsight.springer.com/drugs/800048000
9. Buy Sintilimab Biosimilar - Anti-PDCD1/PD1/CD279 mAb - Research Grade Online, accessed July 18, 2025, https://us.proteogenix.science/product/sintilimab-biosimilar-anti-pdcd1-pd1-cd279-mab-research-grade/
10. Sintilimab: A Promising Anti-Tumor PD-1 Antibody - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/33324564/
11. Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer - PR Newswire, accessed July 18, 2025, https://www.prnewswire.com/news-releases/lilly-announces-complete-response-letter-for-sintilimab-in-combination-with-pemetrexed-and-platinum-chemotherapy-for-the-first-line-treatment-of-people-with-nonsquamous-non-small-cell-lung-cancer-301509537.html
12. China's NMPA Approves Innovent's Anti-PD-1 Antibody Tyvyt® (Sintilimab injection) for Hodgkin's Lymphoma - BioSpace, accessed July 18, 2025, https://www.biospace.com/china-s-nmpa-approves-innovent-s-anti-pd-1-antibody-tyvyt-sintilimab-injection-for-hodgkin-s-lymphoma
13. In Expected Decision, FDA Rejects Lilly's Sintilimab in NSCLC - BioSpace, accessed July 18, 2025, https://www.biospace.com/fda-rejects-lilly-s-sintilimab-in-lung-cancer
14. Sintilimab versus placebo in combination with chemotherapy as first ..., accessed July 18, 2025, https://www.bmj.com/content/377/bmj-2021-068714
15. pubmed.ncbi.nlm.nih.gov, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/30742278/#:~:text=Sintilimab%20(Tyvyt%C2%AE)%20is%20a,endogenous%20antitumour%20T%2Dcell%20response.
16. Sintilimab: A Promising Anti-Tumor PD-1 Antibody - PMC, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7726413/
17. The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China - PMC, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7990150/
18. Sintilimab: First Global Approval - Sci-Hub, accessed July 18, 2025, https://sci-hub.se/downloads/2019-02-12/19/10.1007@s40265-019-1066-z.pdf
19. Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients | ClinicalTrials.gov, accessed July 18, 2025, https://clinicaltrials.gov/study/NCT06883136
20. Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC | ClinicalTrials.gov, accessed July 18, 2025, https://clinicaltrials.gov/study/NCT03629925
21. A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients | ClinicalTrials.gov, accessed July 18, 2025, https://www.clinicaltrials.gov/study/NCT04177290
22. Research progress of sintilimab in the treatment of cancer (Review), accessed July 18, 2025, https://www.spandidos-publications.com/10.3892/ol.2025.14986/download
23. Preclinical characterization of Sintilimab, a fully human anti-PD-1 ..., accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7990132/
24. Sintilimab for R/R classical HL patients: Results from the ORIENT-1 ..., accessed July 18, 2025, https://lymphomahub.com/medical-information/sintilimab-for-rr-classical-hl-patients-results-from-the-orient-1-phase-ii-trial
25. Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study. - ASCO Publications, accessed July 18, 2025, https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.8034
26. First-line Sintilimab Plus Platinum-Based Chemotherapy Prolongs PFS in Advanced Nonsquamous NSCLC, accessed July 18, 2025, https://www.ilcn.org/first-line-sintilimab-plus-platinum-based-chemotherapy-prolongs-pfs-in-advanced-nonsquamous-nsclc/
27. ORIENT-11 Trial Shows Sintilimab Plus Chemotherapy Improves Progression-Free Survival in Advanced NSCLC - The ASCO Post, accessed July 18, 2025, https://ascopost.com/issues/september-10-2020/orient-11-trial-shows-sintilimab-plus-chemotherapy-improves-progression-free-survival-in-advanced-nsclc/
28. FDA's ODAC Votes No to Approval of Frontline Sintilimab ..., accessed July 18, 2025, https://www.targetedonc.com/view/fda-s-odac-votes-no-to-approval-of-frontline-sintilimab-chemotherapy-in-nonsquamous-nsclc
29. Sintilimab Moves Forward With FDA Acceptance of Application in Nonsquamous NSCLC, accessed July 18, 2025, https://www.cancernetwork.com/view/sintilimab-moves-forward-with-fda-acceptance-of-application-in-nonsquamous-nsclc
30. ORIENT-12 Study demonstrates adding sintilimab to gemcitabine ..., accessed July 18, 2025, https://www.iaslc.org/iaslc-news/press-release/orient-12-study-demonstrates-adding-sintilimab-gemcitabine/platinum
31. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12) - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/34048947/
32. Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous Non-Small Cell Lung Cancer - PR Newswire, accessed July 18, 2025, https://www.prnewswire.com/news-releases/innovent-and-lilly-jointly-announce-the-china-nmpa-approval-of-tyvyt-sintilimab-injection-in-combination-with-gemcitabine-and-platinum-chemotherapy-as-first-line-therapy-for-people-with-squamous-non-small-cell-lung-cancer-301304894.html
33. Sintilimab Plus Bevacizumab and Chemo Prolongs PFS in TKI-Refractory EGFR+ NSCLC, accessed July 18, 2025, https://www.targetedonc.com/view/sintilimab-plus-bevacizumab-and-chemo-prolongs-pfs-in-tki-refractory-egfr-nsclc
34. The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy - PR Newswire, accessed July 18, 2025, https://www.prnewswire.com/news-releases/the-china-nmpa-approves-tyvyt-sintilimab-injection-in-combination-with-bevacizumab-and-chemotherapy-in-patients-with-egfr-mutated-non-squamous-nsclc-who-progressed-after-egfr-tki-therapy-301819664.html
35. Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) - Cancer Trial Results, accessed July 18, 2025, https://clin.larvol.com/trial-detail/NCT03748134
36. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study - ResearchGate, accessed July 18, 2025, https://www.researchgate.net/publication/354745595_LBA52_Sintilimab_plus_chemotherapy_versus_chemotherapy_as_first-line_therapy_in_patients_with_advanced_or_metastatic_esophageal_squamous_cell_cancer_First_results_of_the_phase_III_ORIENT-15_study
37. Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma - BioSpace, accessed July 18, 2025, https://www.biospace.com/innovent-and-lilly-jointly-announce-the-approval-of-tyvyt-sintilimab-injection-by-china-nmpa-in-combination-with-chemotherapy-as-first-line-treatment-of-advanced-or-metastatic-gastric-or-gastroesophageal-junction-adenocarcinoma
38. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial - PMC - PubMed Central, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10698618/
39. Press Release - Innovent Biologics, accessed July 18, 2025, https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=275
40. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/38051328/
41. Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer - PR Newswire, accessed July 18, 2025, https://www.prnewswire.com/apac/news-releases/innovent-and-hutchmed-jointly-announce-nmpa-conditional-approval-for-tyvyt-sintilimab-injection-in-combination-with-elunate-fruquintinib-for-the-treatment-of-advanced-endometrial-cancer-302320737.html
42. Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer - BioSpace, accessed July 18, 2025, https://www.biospace.com/press-releases/innovent-and-hutchmed-jointly-announce-nmpa-conditional-approval-for-tyvyt-sintilimab-injection-in-combination-with-elunate-fruquintinib-for-the-treatment-of-advanced-endometrial-cancer
43. Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer - PR Newswire, accessed July 18, 2025, https://www.prnewswire.com/news-releases/innovent-and-hutchmed-jointly-announce-nmpa-conditional-approval-for-tyvyt-sintilimab-injection-in-combination-with-elunate-fruquintinib-for-the-treatment-of-advanced-endometrial-cancer-302320733.html
44. Solid Neoplasms Recruiting Phase Trials for Sintilimab (DB15765) | DrugBank Online, accessed July 18, 2025, https://go.drugbank.com/indications/DBCOND0055654/clinical_trials/DB15765?phase=&status=recruiting
45. Sintilimab by Innovent Biologics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval - Pharmaceutical Technology, accessed July 18, 2025, https://www.pharmaceutical-technology.com/data-insights/sintilimab-innovent-biologics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/
46. Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma | ClinicalTrials.gov, accessed July 18, 2025, https://clinicaltrials.gov/study/NCT05502991
47. Study Details | Sintilimab in Cancer of Unknown Primary | ClinicalTrials.gov, accessed July 18, 2025, https://clinicaltrials.gov/study/NCT05024968
48. Search for: Other terms: Sintilimab | Card Results | ClinicalTrials.gov, accessed July 18, 2025, https://www.clinicaltrials.gov/search?term=Sintilimab&viewType=Table
49. Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/39276785/
50. Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2). - ASCO Publications, accessed July 18, 2025, https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.4511
51. Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case report and review of the literature - PubMed Central, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9843412/
52. Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature - Annals of Palliative Medicine, accessed July 18, 2025, https://apm.amegroups.org/article/view/61363/html
53. Sequential severe immune-related adverse events induced by PD-1 inhibitor: a case report and literature review - Frontiers, accessed July 18, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1391698/full
54. Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report - PMC, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11798969/
55. Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement, accessed July 18, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-and-innovent-announce-global-expansion-tyvyt-licensing
56. Product Center, accessed July 18, 2025, https://www.innoventbio.com/ScienceAndProducts/Pipeline/ProductCenter
57. Sintilimab: What is it and is it FDA approved? - Drugs.com, accessed July 18, 2025, https://www.drugs.com/history/sintilimab.html
58. FDA Denies Approval of Sintilimab With Chemotherapy for ..., accessed July 18, 2025, https://www.targetedonc.com/view/fda-denies-approval-of-sintilimab-with-chemotherapy-for-nonsquamous-nsclc
59. Sintilimab - Orphanet, accessed July 18, 2025, https://www.orpha.net/en/drug/substance/588603?name=&mode=pat®ion=&status=all
60. EU/3/23/2868 - orphan designation for treatment of peripheral T-cell lymphoma - EMA, accessed July 18, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2868
61. SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas, accessed July 18, 2025, https://ir.sellaslifesciences.com/news/News-Details/2024/SELLAS-Receives-EMA-Orphan-Drug-Designation-for-SLS009-for-Treatment-of-Peripheral-T-cell-Lymphomas/default.aspx
62. EMEA-002919-PIP01-20 - paediatric investigation plan | European Medicines Agency (EMA), accessed July 18, 2025, https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002919-pip01-20
63. Comparison of camrelizumab, pembrolizumab, tislelizumab, and ..., accessed July 18, 2025, https://jtd.amegroups.org/article/view/96416/html
64. Sintilimab Elicits Comparable Safety/Efficacy vs Pembrolizumab in Advanced NSCLC, accessed July 18, 2025, https://www.targetedonc.com/view/sintilimab-elicits-comparable-safety-efficacy-vs-pembrolizumab-in-advanced-nsclc
65. Study Details | Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer | ClinicalTrials.gov, accessed July 18, 2025, https://clinicaltrials.gov/study/NCT04252365
66. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/35311347/